Showing posts with label Histone deacetylase (HDAC) inhibitors. Show all posts
Showing posts with label Histone deacetylase (HDAC) inhibitors. Show all posts
Friday, August 13, 2010
Expert Opinion on Investigational Drugs - Summary: Histone deacetylase (HDAC) inhibitors
Take home message: There are extensive preclinical studies with transformed cells in culture and tumor-bearing animal models, as well as limited clinical studies reported to date, which indicate that HDAC inhibitors will be most useful when used in combination with cytotoxic or other targeted anticancer agents.
Subscribe to:
Posts
(
Atom
)
